CM 101

Drug Profile

CM 101

Alternative Names: GBS toxin; ZD 0101

Latest Information Update: 29 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vanderbilt University
  • Developer TumorEnd
  • Class
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Cancer; Craniocerebral trauma; Psoriasis; Reperfusion injury; Rheumatoid arthritis; Spinal cord injuries; Wounds

Most Recent Events

  • 27 Jul 2006 No development reported - Phase-I for Cancer in USA (IV)
  • 27 Jul 2006 No development reported - Phase-I for Spinal cord injuries in USA (IV)
  • 27 Jul 2006 No development reported - Preclinical for Head injuries in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top